Beth Overmoyer
Impact in
- Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies
Papers in
- Oncology 81
- Cancer Treatment and Pharmacology 33
- HER2/EGFR in Cancer Research 28
- Cancer Immunotherapy and Biomarkers 13
-
- Breast Cancer Treatment Studies 46
- Cancer Genomics and Diagnostics 10
- Co-authors
- P. Kelly Marcom (5 shared papers)Hope S. Rugo (13 shared papers)Eric P. Winer (39 shared papers)Kathy D. Miller (6 shared papers)Linnea Chap (2 shared papers)Afshin Dowlati (8 shared papers)Louis Fehrenbacher (1 shared paper)Amy P. Sing (1 shared paper)
- Journals
- Journal of Clinical Oncology (31 papers)Cancer Research (21 papers)Breast Cancer Research and Treatment (11 papers)Bone Marrow Transplantation (7 papers)Clinical Breast Cancer (6 papers)
- Partner nations
- United StatesBrazilUnited Kingdom
In The Last Decade
Beth Overmoyer
141 papers receiving 6.1k citations
Beth Overmoyer's Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 3.6k
- Cancer Research 1.5k
- Pulmonary and Respiratory Medicine 970
- Radiology, Nuclear Medicine and Imaging 682
- Genetics 275
Countries citing papers authored by Beth Overmoyer
This map shows the geographic impact of Beth Overmoyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Overmoyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Overmoyer more than expected).
Fields of papers citing papers by Beth Overmoyer
This network shows the impact of papers produced by Beth Overmoyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Overmoyer. The network helps show where Beth Overmoyer may publish in the future.
Co-authors
The 25 scholars most cited alongside Beth Overmoyer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 145 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer Hit paper breakdown → | 2005 | 1006 |
| 2 | Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas Hit paper breakdown → | 2005 | 504 |
| 3 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer Hit paper breakdown → | 2015 | 464 |
| 4 | 2005 | 420 | |
| 5 | A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. | 2002 | 348 |
| 6 | 2005 | 291 | |
| 7 | 2003 | 254 | |
| 8 | 1994 | 208 | |
| 9 | 2010 | 121 | |
| 10 | 2020 | 115 | |
| 11 | 2018 | 109 | |
| 12 | 1997 | 105 | |
| 13 | 2004 | 103 | |
| 14 | 2008 | 89 | |
| 15 | 2009 | 80 | |
| 16 | 2016 | 72 | |
| 17 | Uniformity of liver density and nonheme (storage) iron distribution. | 1987 | 63 |
| 18 | 2016 | 61 | |
| 19 | Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. | 2002 | 61 |
| 20 | 2018 | 60 |
About Beth Overmoyer
Beth Overmoyer is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Genetics, having authored 145 papers that have together received 6.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (46 papers), Cancer Treatment and Pharmacology (33 papers), HER2/EGFR in Cancer Research (28 papers), Advanced Breast Cancer Therapies (25 papers), Cancer Immunotherapy and Biomarkers (13 papers), Cancer Genomics and Diagnostics (10 papers), Breast Lesions and Carcinomas (9 papers) and Lung Cancer Treatments and Mutations (8 papers). The work is most often cited by research in Oncology (3.6k citations), Cancer Research (1.5k citations), Pulmonary and Respiratory Medicine (970 citations), Radiology, Nuclear Medicine and Imaging (682 citations) and Genetics (275 citations). Beth Overmoyer has collaborated with scholars based in United States, Brazil and United Kingdom. Frequent co-authors include P. Kelly Marcom, Hope S. Rugo, Eric P. Winer, Kathy D. Miller, Linnea Chap, Afshin Dowlati, Louis Fehrenbacher, Amy P. Sing, Melody Cobleigh and Virginia K. Langmuir. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Breast Cancer Research and Treatment, Bone Marrow Transplantation and Clinical Breast Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.